4.9.1.3Vertical

mRNA & Nucleic Acid Therapeutics

Companies developing mRNA, antisense oligonucleotide, siRNA, and other nucleic acid platforms for infectious disease, oncology, rare genetic, and cardiovascular indications.

Market snapshot

These figures describe Biotech & Biopharmaceuticals (4.9.1), the segment that mRNA & Nucleic Acid Therapeutics sits within — not mRNA & Nucleic Acid Therapeutics on its own.

Market size
~$211B
Growth
~1.4%CAGR (2017–22, nominal)
Companies
~2,600
FragmentationConsolidatingEstimate

U.S. Census Bureau 2022 CBP/Economic Census, NAICS 325411 + 325412 + 325414 (pharmaceutical/biological manufacturing) — U.S. manufacturing receipts; the global, IP-driven market is far larger.

Business model & economics

Revenue model

Patent-protected drug sales and royalties

Key economics

Recurring revenue
Moderate

on-patent franchises; cliffs reset it

EBITDA margin
High for branded on-patent drugs
Capex intensity
High

Characteristics

  • The innovation engine of healthcare — high-risk, R&D-intensive.
  • Patent cliffs drive constant pipeline-replenishing M&A.
  • GLP-1/obesity franchise reshaped sector growth.

Geographic concentration

AlabamaAlaskaArizonaColoradoFloridaGeorgiaIndianaKansasMaineMinnesotaNew JerseyNorth DakotaOklahomaPennsylvaniaSouth DakotaTexasWyomingConnecticutMissouriWest VirginiaIllinoisNew MexicoArkansasDelawareDistrict of ColumbiaHawaiiIowaKentuckyMarylandMichiganMississippiMontanaNew HampshireNew YorkOhioOregonTennesseeUtahVirginiaWashingtonWisconsinNebraskaSouth CarolinaIdahoNevadaVermontLouisianaRhode IslandMassachusettsNorth CarolinaCalifornia

Biotech and biopharmaceutical operations concentrate in the established life-sciences clusters — California (the Bay Area and San Diego), Massachusetts (Greater Boston), and North Carolina's Research Triangle — by far the largest centers of industry employment.

CaliforniaMassachusettsNorth Carolina

U.S. Census Bureau — 2022 County Business Patterns (employment by state), NAICS 325411/325412/325414. Leading states by biopharmaceutical employment.

M&A deal context

Deal activityHigh

Who’s acquiring

  • Big pharma & biopharma strategics
  • Biotech-acquiring platforms
  • VC- and crossover-backed biotech

What’s driving deals

  • Patent-cliff-driven acquisition of biotech pipelines.
  • GLP-1 and novel-modality competition.
  • Biotech funding cycles and platform deals.

Find mRNA & Nucleic Acid Therapeutics acquisition targets

Search Acquisera’s index for companies classified under mRNA & Nucleic Acid Therapeutics (4.9.1.3) and build a targeted deal pipeline.

Search companies